Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Plasmablastic Lymphoma × Dexamethasone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 337 Neoplasms, Plasma Cell 56 Precursor Cell Lymphoblastic Leukemia-Lymphoma 54 Recurrence 50 Lymphoma 48 Leukemia 39 Neoplasms 27 Lymphoma, Mantle-Cell 27 Burkitt Lymphoma 26 Immunoglobulin Light-chain Amyloidosis 23 Lymphoma, Large B-Cell, Diffuse 22 Waldenstrom Macroglobulinemia 21 Lymphoma, Non-Hodgkin 21 Lymphoma, Follicular 17 Leukemia, Lymphocytic, Chronic, B-Cell 16 Hodgkin Disease 14 Nausea 12 Lymphoma, Extranodal NK-T-Cell 12 Lymphoma, B-Cell, Marginal Zone 12 Vomiting 11 Smoldering Multiple Myeloma 11 Prostatic Neoplasms 11 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11 Breast Neoplasms 11 Renal Insufficiency 10 Neoplasm Metastasis 9 Lymphoma, Large-Cell, Immunoblastic 9 Carcinoma, Non-Small-Cell Lung 9 Lung Neoplasms 8 Leukemia, Biphenotypic, Acute 7

Interventions

varlilumab 1 daratumumab 1 belantamab mafodotin 1 Vincristine 1 Rituximab 1 Prednisone 1 Nivolumab 1 Immunoglobulin G 1 Etoposide 1 Doxorubicin 1 Disulfides 1 Dexamethasone 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡